menu
    • menu
    [{"orgOrder":0,"company":"NeurOp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Np-10679","moa":"GluN2B","graph1":"Neurology","graph2":"Phase I","graph3":"NeurOp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NeurOp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeurOp \/ Undisclosed"},{"orgOrder":0,"company":"NeurOp","sponsor":"Seyltx","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Np-10679","moa":"GluN2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"NeurOp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NeurOp \/ Seyltx","highestDevelopmentStatusID":"6","companyTruncated":"NeurOp \/ Seyltx"}]

    Find Clinical Drug Pipeline Developments & Deals for Np-10679

    Menu

    Np-10679

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NeurOp

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            NeurOp

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Np-10679

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Seyltx

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Seyltx Expands GluN2B Antagonist Pipeline with Clinical-Stage and Small-Molecules

                            Details : Seyltx obtained an option to license a GluN2B antagonist portfolio, including the Phase 1 candidate NP10679, to broaden its pipeline for chronic and IPF-associated cough.

                            Product Name : NP10679

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 05, 2025

                            Lead Product(s) : Np-10679

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Seyltx

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NeurOp

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            NeurOp

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Np-10679

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NeurOp Receives FDA Orphan Drug Designation for NP10679 for Treatment of Subarachnoid Hemorrhage

                            Details : FDA granted ODD to NP10679, NMDA receptor inhibitor, demonstrated safety, tolerability and positive pharmacokinetics in Phase 1 studies makes an ideal candidate for prophylactic treatment for SAH.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2021

                            Lead Product(s) : Np-10679

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth